MA37472A1 - Composés hétérocycliques et leurs utilisations - Google Patents
Composés hétérocycliques et leurs utilisationsInfo
- Publication number
- MA37472A1 MA37472A1 MA37472A MA37472A MA37472A1 MA 37472 A1 MA37472 A1 MA 37472A1 MA 37472 A MA37472 A MA 37472A MA 37472 A MA37472 A MA 37472A MA 37472 A1 MA37472 A1 MA 37472A1
- Authority
- MA
- Morocco
- Prior art keywords
- inflammatory
- acute
- lla
- diseases
- disorders
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 101001024630 Drosophila melanogaster RNA cytidine acetyltransferase Proteins 0.000 abstract 1
- 101000652705 Drosophila melanogaster Transcription initiation factor TFIID subunit 4 Proteins 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 101000996915 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleoporin NSP1 Proteins 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 abstract 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000002949 hemolytic effect Effects 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des hétéroaryles bicycliques substitués et des compositions les contenant, pour le traitement d'une inflammation générale, de l'arthrite, de maladies rhumatismales, de l'arthrose, de troubles inflammatoires intestinaux, de troubles oculaires inflammatoires, de troubles inflammatoires ou de vessie instable, du psoriasis, d'affections cutanées avec composantes inflammatoires, d'états inflammatoires chroniques, y compris mais de façon non limitative, les maladies auto-immunes telles que le lupus érythémateux disséminé (led), la myasthénie grave, l'arthrite rhumatoïde, l'encéphalomyélite aiguë disséminée, le purpura thrombocytopénique idiopathique, la sclérose en plaques, le syndrome de sjögren et l'anémie hémolytique auto-immune, les états allergiques comprenant toutes formes d'hypersensibilité. La présente invention concerne également des méthodes de traitement de cancers qui sont médiés par, dépendants de ou associés à l'activité p110, y compris mais de façon non limitative, des leucémies, telles que la leucémie myéloïde aiguë (lma), le syndrome myélodysplasique (smd), les maladies myélo-prolifératives (smp), la leucémie myéloïde chronique (lmc), la leucémie lymphoblastique aiguë à cellules t (lla-t), la leucémie lymphoblastique aiguë à cellules b (lla-b), le lymphome non hodgkinien (lnh), le lymphome à cellules b et les tumeurs solides, telles que le cancer du sein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620270P | 2012-04-04 | 2012-04-04 | |
| PCT/US2013/035203 WO2013152150A1 (fr) | 2012-04-04 | 2013-04-04 | Composés hétérocycliques et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37472A1 true MA37472A1 (fr) | 2016-09-30 |
Family
ID=48142975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37472A MA37472A1 (fr) | 2012-04-04 | 2013-04-04 | Composés hétérocycliques et leurs utilisations |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8716290B2 (fr) |
| EP (1) | EP2834231B1 (fr) |
| JP (1) | JP2015512451A (fr) |
| KR (1) | KR20140139547A (fr) |
| CN (1) | CN104395305A (fr) |
| AP (1) | AP3611A (fr) |
| AU (1) | AU2013243506A1 (fr) |
| CA (1) | CA2869413A1 (fr) |
| CL (1) | CL2014002686A1 (fr) |
| CO (1) | CO7091181A2 (fr) |
| CR (1) | CR20140503A (fr) |
| CY (1) | CY1117487T1 (fr) |
| DK (1) | DK2834231T3 (fr) |
| EA (1) | EA201491823A1 (fr) |
| ES (1) | ES2577109T3 (fr) |
| HR (1) | HRP20160352T1 (fr) |
| HU (1) | HUE028762T2 (fr) |
| IL (1) | IL234822A0 (fr) |
| MA (1) | MA37472A1 (fr) |
| ME (1) | ME02473B (fr) |
| MX (1) | MX2014011970A (fr) |
| PE (1) | PE20142457A1 (fr) |
| PH (1) | PH12014502246A1 (fr) |
| PL (1) | PL2834231T3 (fr) |
| RS (1) | RS54716B1 (fr) |
| SG (1) | SG11201406316VA (fr) |
| SI (1) | SI2834231T1 (fr) |
| SM (1) | SMT201600211B (fr) |
| TN (1) | TN2014000412A1 (fr) |
| WO (1) | WO2013152150A1 (fr) |
| ZA (1) | ZA201407037B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013005567A (es) * | 2010-11-17 | 2013-10-30 | Amgen Inc | Derivados de quinolina como inhibidores de pik3. |
| ME02473B (fr) * | 2012-04-04 | 2017-02-20 | Amgen Inc | Composés hétérocycliques et leurs utilisations |
| WO2015171725A1 (fr) | 2014-05-06 | 2015-11-12 | Amgen Inc. | Formes hydratées, cristallines hydratées et cristallines anhydres de la n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)éthyl)-9h-purine-6-amine, compositions pharmaceutiques en contenant et méthodes de traitement du cancer |
| HK1232227A1 (zh) | 2014-07-04 | 2018-01-05 | Lupin Limited | 作为pi3k抑制剂的喹嗪酮衍生物 |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| EP3400227B1 (fr) * | 2016-03-05 | 2021-03-31 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Analogues de quinoléine en tant qu'inhibiteurs de phosphatidylinositol 3-kinase |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TWI853009B (zh) * | 2019-03-29 | 2024-08-21 | 瑞士商先正達農作物保護公司 | 殺有害生物活性之二-醯胺化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| EP1763526B1 (fr) * | 2004-06-28 | 2009-06-24 | Bayer Schering Pharma AG | Pyrimidines 4,6-disubstituees et leur utilisation comme inhibiteurs des proteines kinases |
| EP2139882B1 (fr) * | 2007-03-23 | 2013-12-25 | Amgen Inc. | Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k) |
| EP2231641B1 (fr) * | 2007-12-21 | 2016-06-01 | UCB Biopharma SPRL | Dérivés de quinoxaline et de quinoléine en tant qu'inhibiteurs de kinase |
| WO2010065923A2 (fr) * | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Médicaments à ciblage phosphatidylinositol-3-kinase p110 delta dans le traitement des troubles du snc |
| SG176986A1 (en) * | 2009-06-25 | 2012-02-28 | Amgen Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| MX2012006953A (es) * | 2009-12-18 | 2012-10-09 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| MX2012015134A (es) * | 2010-07-02 | 2013-05-06 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k. |
| ME02473B (fr) * | 2012-04-04 | 2017-02-20 | Amgen Inc | Composés hétérocycliques et leurs utilisations |
-
2013
- 2013-04-04 ME MEP-2016-61A patent/ME02473B/fr unknown
- 2013-04-04 AP AP2014007979A patent/AP3611A/xx active
- 2013-04-04 RS RS20160272A patent/RS54716B1/sr unknown
- 2013-04-04 CN CN201380017551.2A patent/CN104395305A/zh active Pending
- 2013-04-04 HR HRP20160352TT patent/HRP20160352T1/hr unknown
- 2013-04-04 SI SI201330170A patent/SI2834231T1/sl unknown
- 2013-04-04 WO PCT/US2013/035203 patent/WO2013152150A1/fr not_active Ceased
- 2013-04-04 US US13/856,500 patent/US8716290B2/en active Active
- 2013-04-04 EP EP13717655.8A patent/EP2834231B1/fr active Active
- 2013-04-04 DK DK13717655.8T patent/DK2834231T3/en active
- 2013-04-04 AU AU2013243506A patent/AU2013243506A1/en not_active Abandoned
- 2013-04-04 CA CA2869413A patent/CA2869413A1/fr not_active Abandoned
- 2013-04-04 MX MX2014011970A patent/MX2014011970A/es unknown
- 2013-04-04 PE PE2014001529A patent/PE20142457A1/es not_active Application Discontinuation
- 2013-04-04 PL PL13717655T patent/PL2834231T3/pl unknown
- 2013-04-04 EA EA201491823A patent/EA201491823A1/ru unknown
- 2013-04-04 SG SG11201406316VA patent/SG11201406316VA/en unknown
- 2013-04-04 ES ES13717655.8T patent/ES2577109T3/es active Active
- 2013-04-04 HU HUE13717655A patent/HUE028762T2/en unknown
- 2013-04-04 MA MA37472A patent/MA37472A1/fr unknown
- 2013-04-04 KR KR1020147028346A patent/KR20140139547A/ko not_active Withdrawn
- 2013-04-04 JP JP2015504713A patent/JP2015512451A/ja not_active Ceased
-
2014
- 2014-03-21 US US14/221,499 patent/US8835432B2/en active Active
- 2014-09-23 IL IL234822A patent/IL234822A0/en unknown
- 2014-09-26 ZA ZA2014/07037A patent/ZA201407037B/en unknown
- 2014-09-30 TN TNP2014000412A patent/TN2014000412A1/fr unknown
- 2014-10-03 CL CL2014002686A patent/CL2014002686A1/es unknown
- 2014-10-03 PH PH12014502246A patent/PH12014502246A1/en unknown
- 2014-10-07 CO CO14222148A patent/CO7091181A2/es unknown
- 2014-10-30 CR CR20140503A patent/CR20140503A/es unknown
-
2016
- 2016-04-26 CY CY20161100347T patent/CY1117487T1/el unknown
- 2016-07-05 SM SM201600211T patent/SMT201600211B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37472A1 (fr) | Composés hétérocycliques et leurs utilisations | |
| MA34212B1 (fr) | Composés hétérocycliques et leurs utilisations | |
| EA201270013A1 (ru) | Гетероциклические соединения и их применение | |
| EA200901276A1 (ru) | Гетероциклические соединения и их применение | |
| PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| MX2012015134A (es) | Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k. | |
| MX2013007261A (es) | Compuestos heterociclicos y sus usos. | |
| MX2012015135A (es) | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. | |
| MX2009010050A (es) | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). | |
| MA41251B1 (fr) | Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk | |
| MX2011013901A (es) | Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. | |
| MX2011013666A (es) | Compuestos heterociclicos y sus usos. | |
| MX2009009913A (es) | Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres. | |
| MX2011013667A (es) | Compuestos heterociclicos y sus usos. | |
| PH12015500963A1 (en) | Tricyclic fused thiophene derivatives as jak inhibitors | |
| MX2012015143A (es) | Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta. | |
| EA034135B9 (ru) | Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов | |
| EA201891067A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ | |
| MX2012015147A (es) | Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k. | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| EP3432872A4 (fr) | Compositions et méthodes pour l'utilisation d'éflornithine et de dérivés et analogues de cette dernière pour le traitement de cancers, dont les gliomes | |
| MX2020009566A (es) | Compuestos como moduladores de la se?alizacion de tlr2. | |
| JOP20200272A1 (ar) | مُعدّلات تفارغية سبيروبيريدين لمستقبلات أستيل كولين نيكوتينية | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 |